Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
1. Ayrmid Ltd proposed to acquire Bluebird for $4.50 per share. 2. Previous agreement with Carlyle and SK Capital offered $3.00 per share. 3. Bluebird faced FDA concerns over treatment-related malignancies in November 2024. 4. Stock price rose 7.84%, reaching $4.40 after the proposal. 5. Board is reviewing Ayrmid’s bid with legal and financial advisors.